CD20 是一种 33-37 kDa 非糖基化蛋白,特异性表达于正常和恶性 B 淋巴细胞表面,属于 MS4A(跨膜 4 结构域家族 A)蛋白家族。CD20 是一种通用 B 细胞标记物,从晚期前 B 淋巴细胞开始,大多数 B 细胞均有表达(前 B 淋巴细胞不表达),在终末分化的浆母细胞和浆细胞中表达缺失。早期实验表明,它在调节人类 B 细胞活化、增殖和 Ca2+ 转运方面发挥重要作用。然而,CD20 缺陷小鼠似乎正常。因此,CD20 及其生理配体的确切生物学功能仍有待完全确定。240 尽管这种抗原的生物学作用尚不确定,但它是癌症免疫治疗的良好靶点。
CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.
BMS-986458 是一种高选择性、口服有效的 cereblon 型 BCL6 PROTAC 降解剂与抗肿瘤剂,它通过结合 cereblon 与 BCL6 的 BTB 结构域选择性降解 BCL6,进而调控细胞周期、抗增殖及干扰素信号通路并上调 CD20 表达与分布,同时可调节滤泡辅助性 T 细胞表型、降低循环肿瘤 DNA 水平,与 CD20xCD3 双特异性抗体联用还能提升 T 细胞肿瘤浸润与扩增效率,并可诱导 BCL6 阳性肿瘤消退、延长生存期,适用于 B 细胞非霍奇金淋巴瘤、弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤及复发难治性淋巴瘤的相关研究(粉色:BCL6 配体 (MS-X11474);蓝色:Cereblon 配体 (MS-C02328);黑色:连接子 (MS-D73419))。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号